GlassScriptPhysician profile
William Michael Demarchi
NPI 1659353100
$5,808.88
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,599 · 2020: $1,733 · 2021: $1,724 · 2022: $471 · 2023: $178 · 2024: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,147.14 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $694.67 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $550.32 | 2019-2021 | |
| Allergan, INC. | $535.47 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $499.58 | 2019-2023 | Farxiga |
| Pfizer INC. | $343.35 | 2019-2022 | |
| Lilly USA, LLC | $294.77 | 2019-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $285.05 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.33 | 2019-2022 | |
| Abbvie INC. | $185.16 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $151.55 | 2019-2021 | |
| Amgen INC. | $138.11 | 2019-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $110.18 | 2019-2023 | |
| Eisai INC. | $101.96 | 2020-2021 | |
| Abbott Laboratories | $73.74 | 2021-2023 | Freestyle Libre 2 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $71.48 | 2021-2022 | |
| Esperion Therapeutics, INC. | $56.98 | 2021-2023 | Nexletol |
| Boston Scientific Corporation | $55.89 | 2024 | Watchman Flx |
| Exact Sciences Corporation | $45.51 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $41.39 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.09 | 2019 | |
| Angiodynamics, INC. | $30.00 | 2022 | |
| Sumitomo Pharma America, INC. | $26.89 | 2023 | Gemtesa |
| Genzyme Corporation | $23.81 | 2019 | |
| Smith+Nephew, INC. | $20.47 | 2021 | |
| Redhill Biopharma INC. | $18.47 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.27 | 2021 | |
| Corcept Therapeutics | $16.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Demarchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.